Paradigm Shift

In Cancer Treatment

Learn More

Salarius is a cancer-focused biotechnology company developing treatments for patients who need them the most.

Our technology targets the epigenetic causes of cancer which is the study of the regulatory system that controls how genes are turned “on” or “off.” In certain cancers, the proteins that regulate gene expression become dysregulated and incorrectly turn genes “on” or “off,” which in some cases leads to cancer progression. Drugs that are able to safely modify the activity of these epigenetic regulators may correct the gene changes that are driving disease. Our technology may also apply to hormonal cancers such as prostate, breast, ovarian cancer and perhaps other conditions like leukemia.

Salarius is the recipient of a 3-year $18.7 million Cancer Prevention and Research Institute of Texas (CPRIT) New Company Product Development award, is housed in the Jlabs@TMC facility in Houston, Texas and receives support from organizations like the National Pediatric Cancer Foundation.

News & Events

October 28, 2019

Press Release

Salarius Pharmaceuticals and Aspire Capital Announce a $10.9M Common Stock Purchase Agreement

Initial Purchase of $1 Million of Salarius Shares Completed, Aspire Capital to Purchase Additional Salarius Common Stock over a 30-Month Span Extending into 2022

HOUSTON, Oct. 28, 2019 (GLOBE NEWSWIRE) — Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancers, today announced that it has entered into a $10.9 million common stock purchase agreement, including a $1.0 million initial common stock purchase, with Aspire Capital Fund, LLC, a Chicago-based institutional investor.